These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19027738)

  • 1. The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.
    Yoshida T; Okamoto I; Iwasa T; Fukuoka M; Nakagawa K
    FEBS Lett; 2008 Dec; 582(30):4125-30. PubMed ID: 19027738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
    Sato S; Drake AW; Tsuji I; Fan J
    PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Kang HN; Kim SH; Yun MR; Kim HR; Lim SM; Kim MS; Hong KW; Kim SM; Kim H; Pyo KH; Park HJ; Han JY; Youn HA; Chang KH; Cho BC
    Lung Cancer; 2016 May; 95():57-64. PubMed ID: 27040853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).
    Schiller JH
    Cancer Invest; 2008 Feb; 26(1):81-95. PubMed ID: 18181050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.
    Modjtahedi H; Dean C
    Biochem Biophys Res Commun; 1995 Feb; 207(1):389-97. PubMed ID: 7857293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
    Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
    Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.
    Dixit M; Yang JL; Poirier MC; Price JO; Andrews PA; Arteaga CL
    J Natl Cancer Inst; 1997 Mar; 89(5):365-73. PubMed ID: 9060958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
    Tang XH; Li M; Deng S; Lu MS
    Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
    Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
    Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial growth factor receptor interacting agents.
    Baselga J; Albanell J
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1041-63. PubMed ID: 12512382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular view of anti-ErbB monoclonal antibody therapy.
    Leahy DJ
    Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer.
    Hsieh CH; Chou YT; Kuo MH; Tsai HP; Chang JL; Wu CW
    Oncogene; 2017 May; 36(21):2946-2956. PubMed ID: 28092674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
    Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
    J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
    Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
    Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.